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Abstract
Background: The anti-EGFR monoclonal antibody cetuximab is used in metastatic colorectal
cancer (CRC), and predicting responsive patients garners great interest, due to the high cost of
therapy. Mutations in the KRAS gene occur in ~40% of CRC and are a negative predictor of
response to cetuximab. However, many KRAS-wildtype patients do not benefit from cetuximab.
We previously published a gene expression predictor of sensitivity to erlotinib, an EGFR inhibitor.
The purpose of this study was to determine if this predictor could identify KRAS-wildtype CRC
patients who will benefit from cetuximab therapy.
Methods: Microarray data from 80 metastatic CRC patients subsequently treated with cetuximab
were extracted from the study by Khambata-Ford et al. The study included KRAS status, response,
and PFS for each patient. The gene expression data were scaled and analyzed using our predictive
model. An improved predictive model of response was identified by removing features in the 180gene predictor that introduced noise.
Results: Forty-three of eighty patients were identified as harboring wildtype-KRAS. When the
model was applied to these patients, the predicted-sensitive group had significantly longer PFS than
the predicted-resistant group (median 88 days vs. 56 days; mean 117 days vs. 63 days, respectively,
p = 0.008). Kaplan-Meier curves were also significantly improved in the predicted-sensitive group
(p = 0.0059, HR = 0.4109. The model was simplified to 26 of the original 180 genes and this further
improved stratification of PFS (median 147 days vs. 56.5 days in the predicted sensitive and resistant
groups, respectively, p < 0.0001). However, the simplified model will require further external
validation, as features were selected based on their correlation to PFS in this dataset.
Conclusion: Our model of sensitivity to EGFR inhibition stratified PFS following cetuximab in
KRAS-wildtype CRC patients. This study represents the first true external validation of a molecular
predictor of response to cetuximab in KRAS-WT metastatic CRC. Our model may hold clinical
utility for identifying patients responsive to cetuximab and may therefore minimize toxicity and cost
while maximizing benefit.
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Background
A wealth of clinical data has confirmed the role of using
KRAS mutational status to stratify advanced-stage colorectal cancer (CRC) patients to receive anti-EGFR monoclonal antibody (mAB) therapy [1-7]. Activating KRAS
mutations are strong independent negative predictors of
response to such treatment and mutational testing has
been included in colorectal cancer practice guidelines.
Interestingly, KRAS mutations may also predict lack of
response to EGFR tyrosine kinase inhibitors (TKI) in lung
cancer, suggesting a common mechanism of resistance to
anti-EGFR therapies in these two tumor types [8-10].
Importantly, a large percent of lung cancer and CRC
patients harboring wildtype KRAS, do not realize benefit
from EGFR-targeted agents [1,3,5,7]. Therefore, additional methods of patient stratification are required to
improve the tailoring of EGFR-targeted therapy in these
diseases.
We have previously published a gene expression predictor
of response (GEPR) to erlotinib in lung cancer [11]. The
180-gene model was built on Affymetrix microarray data
and genes were selected and weighted based on the
expression data from a series of lung cancer cell lines with
known sensitivities to erlotinib. The model was externally
validated using additional lung cancer cell lines as well as
in human tumors (reference 11 and unpublished data).
Given the correlation between KRAS mutational status
and response to both EGFR-mAB and EGFR-TKI in lung
and colorectal tumors, we hypothesized that our previously published GEPR is capable of predicting response to
cetuximab in metastatic CRC.
Khambata-Ford and colleagues conducted a study with
over 100 CRC patients wherein metastatic sites were biopsied, mutational status of KRAS was determined, and gene
expression data was generated [12]. Following the biopsy,
patients were treated with cetuximab as monotherapy and
response and progression-free survival were recorded. The
purpose of that study was to identify predictive biomarkers for response to cetuximab.
The publication of these data presented an excellent
opportunity to test our hypothesis that the 180-gene
GEPR to erlotinib generated in lung adenocarcinoma cell
lines was portable to KRAS-wildtype CRC in predicting
response to cetuximab. Since the data published by
Khambata-Ford and colleagues was not available until
almost a year following the publication of our predictive
model, the data could be utilized to perform a true external validation, essentially equivalent to an independent
prospective study due to the sequence and timing of the
involved publications.
The primary endpoint of our study was to test the ability
of our predictive algorithm to segregate cetuximab
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responders from non-responders in the KRAS-wildtype
population included in the Khambata-Ford study. We
found that our GEPR of erlotinib response was strongly
predictive of cetuximab response with no gene-weighting
adjustment or additional gene selection. However, reducing the signature to 26 of 180 genes based on the correlation of those genes to survival in the Khambata-Ford
dataset significantly improved the predictive accuracy and
Kaplan Meier curve separation. Importantly, the refined
signature retained the original weights from the NSCLC
model-training data, reducing the likelihood of over-fitting.
The most significant finding of this study was that the
GEPR was capable of predicting progression-free survival
in another tumor type than that on which the model was
built, and with another EGFR-targeted agent. Similarly,
other groups have previously reported portability of gene
expression signatures [13,14]. We believe that this model
could be highly useful in predicting response to cetuximab in CRC in patients with KRAS-wildtype tumors. Furthermore, additional studies to validate the predictive
capacity of the model in other appropriate tumor types are
underway.

Methods
Gene expression predictor of response to EGFR-targeted
agents
The GEPR to EGFR-targeted agents was built using lung
cancer cell lines and sensitivity data to the EGFR-tyrosine
kinase inhibitor erlotinib. Briefly, the GEPR uses the
MAS5-normalized Affymetrix signal intensity values from
180 genes which are represented on the Affymetrix U133
platform. These features are used to perform diagonal linear discriminant analysis (DLDA) in order to make a
group selection of 'sensitive' or 'resistant' based on the
similarity of the test sample to the 'sensitive' and 'resistant'
training (model) data. The details regarding gene selection, weighting, and methods required to perform the
analysis are reported elsewhere [11]. All predictive analyses for this study were carried out in R statistical language.
Data analysis and prediction
The data from Khambata-Ford et al were extracted in series
matrix format from Gene Expression Omnibus (GEO)
record GSE5851[12]. The data from that study were scaled
by the authors to mean intensity of 1500. Therefore, the
data matrix was multiplied by a factor of 0.333 in order to
reflect the mean intensity value of the data used to generate our GEPR (500). This direct linear relationship was
confirmed by scaling experimental data to both values
using Expression Console (Affymetrix, Santa Clara, CA)
and observing the ratios on a probe by probe basis. A ratio
of precisely 0.333 was observed for all probesets, confirming the validity of this approach to data handling (data
not shown). The clinical response data and KRAS status
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were extracted from the supplementary files provided by
Khambata-Ford et al [12].
No changes were made to the predictive algorithm. The
test matrix was truncated to the 180 predictive genes
included in the original model and imported into R for
DLDA. Details regarding the analysis and model have
been previously reported [11]. Data from the KhambataFord study were separated into three datasets: KRASwildtype, KRAS-mutant, or all patients combined. After
sensitivity prediction on each of the datasets, the results
were imported into Excel (Microsoft, Redmond, WA) and
cross referenced with response and progression free survival (PFS).
Model refinement
The 180 signature genes were filtered for their correlation
to survival in the Khambata-Ford dataset. Specifically,
ratios of gene expression values were calculated for the
best (> 150 days PFS) relative to the worst-performing
patients (< 50 days PFS). These cutoffs were selected based
on the finding that they produced similarly sized cohorts
of patients (approximately 1/3 of the dataset). These
cohorts were used only to determine directionality of the
genes (i.e. up in better-responding or down in betterresponding). Similar ratios were calculated for each gene
for the sensitive relative to resistant training (NSCLC)
dataset. Next, genes which did not display directional concordance were filtered (i.e. genes with calculated ratios in
both datasets > 1 or calculated ratios in both datasets < 1
were retained). This filtering step was performed because
genes which show an association with response in the test
dataset, but in the opposite direction, could confound the
predictive model and are therefore not likely to improve
the accuracy of the test. The remaining genes were further
filtered based on their absolute correlation to PFS in the
Khamabata-Ford dataset. Twenty-six of the original 180
genes were identified that had absolute Pearson's correlation coefficients of ≥ 0.2 and had directional concordance
with the NSCLC model-training data. These 26 features
were retained in the 'refined' model. This procedure was
utilized only as a gene-filtering step, as the original
weighting for these genes in the predictive algorithm was
retained.
Statistical analysis
All statistical analyses were performed using Prism
(Graphpad, La Jolla, CA) and checked using JMP (SAS,
Cary, NC). For comparisons of median progression free
survival, the 2-tailed Mann-Whitney U test was performed
between groups predicted to be sensitive and those predicted to be resistant. Kaplan-Meier survival curves were
generated based on the PFS data reported by KhambataFord et al and analyzed by the log-rank statistic [12].
These analyses were performed on only the KRAS-
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wildtype patient data first, and then repeated on all
patient data as well as the KRAS-mutant population independently for comparison.

Results
The gene expression predictor of response to erlotinib also
predicts response and disease control to cetuximab in
mCRC
The 180-gene GEPR provides a model which weights
genes based on the expression values determined from a
panel of NSCLC cell lines stratified by their sensitivity to
the EGFR inhibitor erlotinib. This model was applied to
the metastatic CRC data from Khambata-Ford et al. The
microarray data from 80 of the 110 patients enrolled in
that study were available for analysis. Of these, 43
(53.8%) were confirmed wildtype and 27 (33.8%) had
confirmed KRAS mutations. The KRAS status of the
remaining 10 (12.5%) patients was not reported.

Since KRAS status is used to determine the CRC patients
who should receive cetuximab, the primary endpoint of
our study was to determine if the GEPR could correctly
stratify KRAS-wildtype patients according to response/disease control. Indeed, when the prediction results were
matched to response as reported by Khambata et al, our
predictive model correctly captured 5/5 partial and complete KRAS-wildtype responders (Figure 1A). Also, 12/15
patients who demonstrated stable disease were classified
as 'sensitive' by the GEPR. Thus, the majority (17/20,
85%) of patients demonstrating overall disease control
(SD+PR+CR) were captured in the 'sensitive' group.
As a secondary endpoint, we wished to determine if the
predictive signature was an independent predictor of
response and/or disease control to cetuximab. To assess
this, we analyzed all of the patient data, irrespective of
KRAS status. Interestingly, when all 80 patients were considered, the GEPR retained predictive capacity (Figure 1B),
although the most significant enrichment (Fisher's exact
test, p = 0.001) of responding and SD patients were
observed when the GEPR was applied only to KRASwildtype patients. No PRs or CRs were noted in KRASmutant patients, consistent with previous findings
[2,5,7,12]. Nonetheless, 2/2 KRAS-mutant patients demonstrating stable disease to cetuximab were captured in
the sensitive group (Figure 1C). Calculated parameters
(specificity, sensitivity, negative predictive value, and positive predictive value) for the ability of the model to predict disease control are given in Table 1. Negative
predictive values were consistently higher than positive
predictive values, regardless of the cohort tested. This indicates that a high number of false positives are associated
with this 180-gene model. However, in the absence of a
genomic data to predict response, most wildtype KRAS
mCRC patients could be considered candidates for cetux-
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Figureclassifications
Group
1
coupled with response data based on the 180-gene GEPR to EGFR-targeted therapy
Group classifications coupled with response data based on the 180-gene GEPR to EGFR-targeted therapy.
Patient populations from Khambata-Ford et al were classified using our predictive model. Percentage of patients exhibiting each
annotated radiographic responses (CR/PR – complete responses and partial responses, SD – stable disease, PD – progressive
disease, NA – not available/not reported) are classified as 'sensitive' or 'resistant' groups. A: KRAS-wildtype patients (43 subjects); B: all patients (80 subjects); and C: KRAS-mutant patients (27 subjects).
imab therapy. Therefore, the false positive rate is less concerning. The high NPV of the test suggests that the test
could be accurately used to identify patients who will not
benefit from anti-EGFR treatment (negative screen).
Table 1: Calculated parameters for the ability of the GEPR to
predict disease control

Parameter
Specificity
Sensitivity
PPV
NPV

KRAS-wildtype

All patients

KRAS-mutant

0.32
0.85
0.57
0.66

0.4
0.8
0.43
0.77

0.5
1
0.18
1

NPV: negative predictive value; PPV positive predictive value

The gene expression predictor of response to erlotinib
stratifies cetuximab-treated mCRC patients based on
progression-free survival
We next determined whether KRAS-wildtype patients
identified by the model as 'sensitive' would exhibit true
clinical benefit when compared to those classified as
'resistant'. Scatter-plots and Kaplan-Meier survival curves
of the progression-free survival (PFS) were generated for
both predicted groups in KRAS-wildtype patients (Figure
2). PFS was significantly greater in the KRAS-wildtype
patients who predicted as 'sensitive' (median PFS: 88
days, mean PFS: 117 days, 95% CI: 90.8 – 143.8 days)
compared to those that predicted as 'resistant' (median
PFS: 56 days, mean PFS: 63 days, 95% CI: 29.9 – 96.9
days) (Figure 2A, left). The difference in PFS was statisti-
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The
metastatic
Figure
180-gene
2 CRC
GEPR
patients
to EGFR-targeted
treated with cetuximab
therapy stratifies a patient population demonstrating longer progression-free survival in
The 180-gene GEPR to EGFR-targeted therapy stratifies a patient population demonstrating longer progression-free survival in metastatic CRC patients treated with cetuximab. The data from Khambata-Ford et al were classified using our predictive model and matched to PFS. The scatter plots (left) depict the individual data points and median PFS
for each group. The Kaplan-Meier survival curves (right) depict PFS between the 'sensitive' (green) and 'resistant' (red) groups.
A: KRAS-wildtype patients; B: all patients; and C: KRAS-mutant patients.
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cally significant between groups (p = 0.0133, two-tailed
Mann-Whitney U test). The difference in the KaplanMeier survival curves was highly statistically significant
when analyzed by the log-rank statistic for the KRASwildtype group (Figure 2A, right).
When the entire cohort was included in the analysis,
regardless of KRAS status, the difference remained statistically significant (p = 0.0254, two-tailed Mann-Whitney U
test) (Figure 2B, left). However, the differences in median
and mean PFS were smaller (median PFS: 60 vs. 57.5 days
and mean PFS: 104.7 vs. 60.5 days in 'sensitive' and 'resistant' subgroups, respectively). The difference in the Kaplan-Meier survival curves retained significance in the
entire cohort, supporting the secondary hypothesis that
the GEPR was an independent predictor of cetuximab
benefit (Figure 2B, right). The PFS in the KRAS-mutant
subgroup, when analyzed independently, was not statistically different between 'sensitive' and 'resistant' subgroups
(Figure 2C).
Refinement of the GEPR improves stratification of survival
in KRAS-WT patients
The 180-gene GEPR was effective in stratifying PFS in
KRAS-WT patients. However, we wished to determine if
the model features, which had been pre-defined, could be
reduced to a suitable number for an alternate analytical
method, such as qRT-PCR. Furthermore, data reduction
could eliminate noisy genes, or those from the original
model that are predictive in NSCLC but not predictive in
colorectal cancer. To test this hypothesis, we filtered the
180 genes based on their directional concordance
between the training data (NSCLC cell lines) and the CRC
data. Genes that were more highly expressed in the sensitive NSCLC cell lines relative to the resistant lines while
also being more highly expressed in CRC patients with a
PFS of > 150 days were retained. Similarly, genes that were
more highly expressed in the resistant NSCLC cell lines
relative to the sensitive cell lines while also being more
highly expressed in CRC patients with a PFS of < 50 days
were retained. Finally, correlations of the remaining genes
with PFS were calculated and those with an absolute value
of correlation ≥ 0.2 were retained while those that were <
0.2 were filtered. A correlation cutoff of |0.2| returned a
suitable number of genes and vastly improved differences
in median survival between the two groups. A cutoff of
|0.3| yielded only 8 genes, which we speculated may have
a decreased likelihood of capturing tumor heterogeneity.
Indeed, this signature did not effectively predict PFS in the
dataset (data not shown). A cutoff of |0.1| yielded 75
genes, which we perceived to be a suboptimal data reduction step. This 75 gene signature improved predictions,
but not as significantly as a cutoff of r = |0.2| (data not
shown). Thus, twenty-six genes comprised the 'refined'
model (Table 2). The weights for the 26 genes were
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retained from the original GEPR, to minimize over-fitting
the model. A heatmap of the signal intensities of the 26
retained genes demonstrated a pattern of deregulation
coincident with PFS (Figure 3A).
When the refined model was applied to the KRAS-WT
CRC data, the resulting difference in PFS between the predicted-sensitive and predicted-resistant group was highly
significant (median 147 days vs. 56.5 days in the predicted sensitive and resistant groups, respectively, p <
0.0001) (Figure 3B and 3C). Kaplan-Meier curves demonstrated significant separation as well. Parameters (sensitivity, specificity, NPV and PPV) for the refined model to
predict disease control (SD/PR/CR) are presented in Table
3. Parameters were improved for the 26-gene model over
the 180-gene model for all cohorts tested. Thus, as we
have demonstrated, the utility of the model is greatly
enhanced by enriching for genes which correlate with PFS.

Discussion
The anti-EGFR monoclonal antibodies cetuximab and
panitumumab are frequently used in metastatic CRC and
improve overall survival when used in unselected populations [15-19]. However, a number of independent studies
have elucidated the correlation of activating mutations in
KRAS with lack of response to EGFR-targeted agents, and
patient stratification based on KRAS status should
improve overall survival through enrichment of responding patients [1-6]. However, a significant number of
KRAS-wildtype patients do not benefit from treatment,
and therefore additional methods to enrich the treated
population for responders are needed to reduce unnecessary toxicity and cost while maximizing therapeutic benefit from these agents. Indeed, Karapetis and colleagues
reached the conclusion that additional biomarker
approaches are needed to identify KRAS-wildtype patients
who will receive benefit from cetuximab in one of the
largest analyses to date of the association of KRAS status
with clinical outcome to cetuximab in CRC [7].
In this study, we utilized a GEPR for erlotinib, an EGFRTKI, which was generated in lung cancer cell lines, to test
its predictive capacity in KRAS-wildtype mCRC patients
treated with the anti-EGFR mAB cetuximab. It is important to note that the GEPR generated in lung cancer cell
lines and was not dependent on either KRAS or EGFR
mutation status. Further, the genes included in the signature demonstrate biological association with pathways
downstream of EGFR, including both the PI3K/AKT and
MAPK pathways [11].
Application of our model to the CRC dataset represents a
true external validation of the GEPR since the validation
set was not available until well after the reporting of our
GEPR model. The availability of this dataset allowed us to
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Table 2: Features of the 26-gene refined model

Gene

Description

Affymetrix Probe ID

DDR1
PRDX4
RYK
HMOX1
GNB5
PIK3CA
ELMO1
GPSM2
PTK7
TNFRSF1A
ECOP
RAC1
RGL2
TNFRSF10B
PRKCI
MAPK13
VEGFA
RHOB
NUDT4
ATP2C1
GNAS
CAMK2G
ITGA6
P2RY5
PRKD2
CC2D1A

discoidin domain receptor tyrosine kinase 1
peroxiredoxin 4
RYK receptor-like tyrosine kinase
heme oxygenase (decycling) 1
guanine nucleotide binding protein (G protein), beta 5
phosphoinositide-3-kinase, catalytic, alpha polypeptide
engulfment and cell motility 1
G-protein signaling modulator 2 (AGS3-like, C. elegans)
PTK7 protein tyrosine kinase 7
tumor necrosis factor receptor superfamily, member 1A
EGFR-coamplified and overexpressed protein
ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1)
ral guanine nucleotide dissociation stimulator-like 2
tumor necrosis factor receptor superfamily, member 10b
protein kinase C, iota
mitogen-activated protein kinase 13
vascular endothelial growth factor A
ras homolog gene family, member B
nudix (nucleoside diphosphate linked moiety X)-type motif 4
ATPase, Ca++ transporting, type 2C, member 1
GNAS complex locus
calcium/calmodulin-dependent protein kinase (CaM kinase) II gamma
integrin, alpha 6
purinergic receptor P2Y, G-protein coupled, 5
protein kinase D2
coiled-coil and C2 domain containing 1A

1007_s_at
201923_at
202853_s_at
203665_at
204000_at
204369_at
204513_s_at
205240_at
207011_s_at
207643_s_at
208091_s_at
208641_s_at
209110_s_at
209295_at
209678_s_at
210058_at
210512_s_at
212099_at
212181_s_at
212255_s_at
212273_x_at
212757_s_at
215177_s_at
218589_at
38269_at
58994_at

determine whether the GEPR could predict response to
alternate EGFR-targeted agents, employ the use of KRAS
status to enrich the predictive power, and function across
tumor types (CRC versus non-small cell lung) [11,12].
Surprisingly, the unaltered 180-gene model had a high
capacity to stratify KRAS-wildtype CRC patients who demonstrated disease control or response to cetuximab treatment. The data were furthered by the significant
separation of the survival curves of the predicted 'sensitive' group versus the predicted 'resistant' group.
Importantly, these results were achieved even though the
genes that comprised the model were selected and
weighted based on the genomic expression in lung cancer
cell lines. Unlike the data reported by Khambata-Ford and
colleagues, neither amphiregulin (AREG) nor epiregulin
(EREG) are included in our GEPR. Further, RNA isolation
from biopsy of metastatic CRC of unknown tumor cell
content and subsequent microarray hybridizations were
all performed at a different facility than our own.
In the original report, Khambata-Ford and colleagues
used AREG and EREG expression to stratify KRASwildtype patients, and found a significant improvement
in PFS in the 'high' ligand expressers group (EREG: P =
.0002, hazard ratio [HR] = 0.47, and median PFS, 103.5 v
57 days, respectively; AREG: P < .0001, HR = 0.44, and
median PFS, 115.5 v 57 days, respectively)[12]. The differ-

ences in median survival reported in that study are greater
than those identified in our study using the original 180gene model. It is not surprising that the authors were able
to demonstrate separation of the survival curves between
high ligand expressers and low ligand expressers because
AREG and EREG were chosen as biomarkers post-hoc.
AREG and EREG were selected from over 600 genes after
the response and progression free survival in the study
population was already determined. Optimal cutoff
expression levels were obtained from a receiver-operator
characteristic (ROC) curve, and changes in median PFS
were then calculated on the same data used to generate
these variables. It has yet to be shown whether AREG and
EREG hold any external validity as predictors of cetuximab response. In contrast, our predictive model was generated prior to the reporting of the Khambata-Ford data
and using these data, provides true external validity of our
model. The improvement in progression-free survival that
we identified in the predicted 'sensitive' KRAS-wildtype
mCRC patients was approximately 1 month. Given that
cetuximab yields an overall benefit in PFS of 1.5 months
as monotherapy in CRC as well as the high cost of treatment, these findings should be considered clinically
important [20].
In light of the cost associated with microarray analysis, we
went on to attempt to reduce the number of predictive
genes necessary to achieve both response prediction and
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Figurerefinement
Model
3
to 26 features improves predictive accuracy
Model refinement to 26 features improves predictive accuracy. A. Heatmap of signal intensities for the 26 genes in the
refined model plotted by clinical sample. All clinical samples were included (KRAS WT, KRAS-mutant, and unconfirmed/NA)
and are arranged according to PFS. Sixty and 120 day PFS are identified on the scale for approximate reference. KRAS-mutant
samples (codon 12) are designated by red arrows. Genes which are more highly expressed in the 'sensitive' training data are
marked with red on the probeset axis, while gene more highly expressed in the 'resistant' training data are marked in green. B.
The confirmed KRAS-WT samples were plotted by predicted sensitivity. Closed circles and bars represent individual PFS and
median PFS for the group, respectively. C. The Kaplan-Meier survival curve depicts PFS between the 'sensitive' (green) and
'resistant' (red) groups. The reported p-value is for the log-rank statistic.

PFS stratification using data from the Khambata-Ford et al
study. In so doing, we found that refining the GEPR, using
a subset of 26 of the original 180 genes, greatly improved
the sensitivity and specificity of the GEPR. Furthermore,
using the refined 26-gene GEPR significantly improved
the difference in median PFS between the predicted-sensitive and predicted-resistant groups and resulted in
improved predictions compared with those reported by

Khambata-Ford et al. Distinct differences in the gene
expression patterns are observed in the gene expression
values (color scheme of the heat map in Figure 3) of the
26 feature signature, clearly identifying a trend which corresponds to PFS. However, the variability of these patterns
observed on a per gene basis highlights the necessity of
using multiple features to capture the heterogeneity of
tumors. As with the Khambata-Ford analysis, careful inter-
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Table 3: Calculated parameters for the ability of the refined (26gene) GEPR to predict disease control

Parameter
Specificity
Sensitivity
PPV
NPV

KRAS-wildtype

All patients

KRAS-mutant

0.74
0.80
0.76
0.78

0.71
0.80
0.63
0.86

0.78
1.00
0.33
1.00

NPV: negative predictive value; PPV positive predictive value

pretation of the predictive accuracy of our refined model
is necessary. Because information from the validation set
was utilized in feature selection, over-fitting remains a
possibility. The refined GEPR reported here retains the
original weights of the 26 genes, reducing the chance of
over-fitting. Additional validation will test that hypothesis
and determine if the 26-gene GEPR can be used in a qRTPCR analysis rather than on an Affymetrix platform.
While the 180-gene GEPR was useful for stratifying KRASwildtype patients, we also wished to determine whether
the GEPR could stratify patients independently of KRAS
status. Statistical significance was retained in both median
PFS and the log-rank analyses when patients were not
stratified based on KRAS status, suggesting that the signature is an independent predictor of benefit to cetuximab
therapy in mCRC. However, patients with KRAS-mutant
CRC tumors who predicted as 'sensitive' did not have
longer PFS than those who predicted as 'resistant',
although this could be due to the small sample size
included in this particular analysis. It is of note that one
patient with a KRAS-mutant tumor was reported by
Khambata et al to have had a PFS of > 1 year on cetuximab, although radiographic response in this patient was
not recorded. Our 180-gene GEPR classified this patient as
'sensitive', offering additional support of the independency of our test from KRAS mutational status. However, a
significant number of non-responding KRAS-mutant
patients were called 'sensitive' by the GEPR, contributing
to a poor positive predictive value in this group.
To further explore the relationship between the GEPR prediction status and KRAS status, we performed a χ2 test. No
association with KRAS status was found in the prediction
outcomes for either the 26-gene (p = 0.2) or the 180-gene
signature (p = 0.3). Thus, our test appears to be independent of KRAS status. On a per gene basis, we also examined
whether any of the 180 genes were significantly different
between the KRAS-wildtype and KRAS-mutant cohorts. Of
the 180 genes, 32 were p < 0.05 according to a two tailed
t-test (although a Bonferroni correction yielded no significantly deregulated genes). However, only 3 of these genes
were included in the final 26 gene signature (ATP2C1,
P2RY5, and TNFRSF10B). Thus, this test offers an explana-

tion for why the 26-gene signature demonstrated
improved predictive accuracy over the 180-gene signature,
as the majority of genes associated with KRAS activation
appear to have been removed during gene list filtering.
Our GEPRs, 180- or 26-gene, may be best utilized in tandem with KRAS-mutational testing. Importantly, our
methodology could easily be combined with KRAS mutational testing through biopsy of metastatic sites and allotment of tissue cores for both RNA and DNA purification.
The high sensitivity and negative predictive value of the
test suggests that use of the model could be implemented
to significantly enrich the responding patient population
while minimizing the number of potential-responders
(i.e. false negatives) who would be diverted from receiving cetuximab.

Conclusion
These data suggest that the 180-gene GEPR will be a valuable clinical tool in determining who should receive
cetuximab therapy in metastatic colorectal cancer, perhaps best used in combination with KRAS status. More
studies will be necessary to determine whether the predictive capacity of the model is retained in patients treated
with cetuximab plus chemotherapy or in patients treated
with panitumumab. Additional validation in NSCLC and
CRC, and potentially other epithelial tumor types, will
confirm the broader clinical utility of this predictive
model, as well as assess the true external validity of the
refined 26-gene model.
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